Whereas much of the current attention surrounding GLP-1 RAs, or glucagon-like peptide-1 receptor agonists, has been focused on their unexpected and potent effect on weight loss, one important aspect of this class of drugs should not be overlooked: GLP-1 RAs have been shown to reduce the risk of heart attack, stroke, and other major adverse cardiovascular events (MACE) in patients with type 2 diabetes who have or are at high risk for atherosclerosis
This insight empowers your doctor to select the right dose faster and to determine whether a dual-compound option like GLP-Squared might amplify your results
Observational studies have demonstrated that individuals with obesity are at substantially higher risk of developing lymphoedema following cancer treatment, and those with established lymphoedema experience greater symptom burden and functional impairment when overweight or obese
Any unanticipated disruption to a future contract manufacturer caused by problems at suppliers could delay shipment of our drug candidates, increase our cost of goods sold and result in lost sales
These medications offer protection against multiple cardiometabolic risks